MedTech Acquisition Corporation
MTAC · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 2.83 | 0.00 | 0.00 |
| FCF Yield | -11.53% | -0.87% | -0.56% | 0.00% |
| EV / EBITDA | -9.80 | -36.77 | -28.66 | 0.00 |
| Quality | ||||
| ROIC | -55.58% | -13.30% | -1.22% | 0.00% |
| Gross Margin | 86.06% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.23 | -0.49 | -0.36 | – |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | -57.47% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.26 | -0.03 | 0.00 |
| Interest Coverage | 11.70 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |